公开(公告)号：EP0692930A1

公开(公告)日：1996-01-24

申请号：EP94910879.0

申请日：1994-03-07

申请人： ISIS PHARMACEUTICALS, INC.

发明人： DRAPER, Kenneth, G. ,  CROOKE, Stanley, T. ,  MIRABELLI, Christopher, K. ,  ECKER, David, J. ,  HANECAK, Ronnie, C. ,  ANDERSON, Kevin, P. ,  BROWN-DRIVER, Vickie, L. ,  WYATT, Jacqueline, R.

IPC分类号： C12N15 ,  A61K31 ,  A61P31 ,  C07H21 ,  C07K14 ,  C12Q1 ,  A61K38

CPC分类号： C12N15/1133 ,  A61K31/70 ,  A61K38/00 ,  C07H21/00 ,  C07K14/005 ,  C12N15/1137 ,  C12N15/117 ,  C12N2310/151 ,  C12N2310/18 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/33 ,  C12N2310/346 ,  C12N2310/3517 ,  C12N2310/3521 ,  C12N2710/16622 ,  C12Q1/701 ,  C12Y207/07049 ,  C12Y301/01004

摘要： Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a herpesvirus gene corresponding to one of the open reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site, a coding region or a 5'-untranslated region. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide of the invention are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

公开(公告)号：EP0517859B1

公开(公告)日：1998-07-22

申请号：EP91908334.5

申请日：1991-02-25

申请人： ISIS PHARMACEUTICALS, INC.

发明人： DRAPER, Kenneth, G. ,  ECKER, David, J. ,  MIRABELLI, Christopher, K. ,  CROOKE, Stanley, T.

IPC分类号： A61K31/70 ,  C12Q1/68 ,  C07H21/02 ,  C07H21/04 ,  A61K48/00

CPC分类号： C12N15/1133 ,  A61K38/00 ,  C07K14/005 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2710/16622

摘要： Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42, and UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

公开(公告)号：EP0517859A1

公开(公告)日：1992-12-16

申请号：EP91908334.0

申请日：1991-02-25

申请人： ISIS PHARMACEUTICALS, INC.

发明人： DRAPER, Kenneth, G. ,  ECKER, David, J. ,  MIRABELLI, Christopher, K. ,  CROOKE, Stanley, T.

IPC分类号： A61K31 ,  A61K48 ,  A61P31 ,  C07H21 ,  C07K14 ,  C12N7 ,  C12N15 ,  C12Q1 ,  A61K38

CPC分类号： C12N15/1133 ,  A61K38/00 ,  C07K14/005 ,  C12N2310/3125 ,  C12N2310/315 ,  C12N2710/16622

摘要： Compositions et procédés de traitement et de diagnostic d'infections dues à l'herpèsvirus. Selon les modes de réalisation préférés, on utilise des oligonucléotides spécifiquement hybridables avec de l'ARN ou de l'ADN dérivant d'un gène correspondant à un des cadres de lecture ouvert UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 et UL52 de l'herpèsvirus type 1. L'oligonucléotide comprend des unités de nucléotides suffisantes en identité et en nombre pour permettre ladite hybridation spécifique. Selon d'autres modes de réalisation, les oligonucléotides sont spécifiquement hybridables avec un site d'amorce de translation; il est également préférable qu'ils comprennent la séquence CAT. L'invention concerne des procédés de traitement d'animaux soupçonnés d'être contaminés par l'herpèsvirus, consistant à mettre en contact l'animal avec un oligonucléotide spécifiquement hybridable avec de l'ARN ou de L'ADN dérivant d'un des gènes précité de l'herpèsvirus. L'invention concerne également des procédés de traitement d'infections provoquées par l'herpèsvirus de type 1, l'herpèsvirus de type 2, le cytomégalovirus, l'herpèsvirus humain 6, le virus d'Epstein Barr ou l'herpèsvirus varicellae.

公开(公告)号：EP0975654A1

公开(公告)日：2000-02-02

申请号：EP98918034.4

申请日：1998-04-07

申请人： ISIS PHARMACEUTICALS, INC.

发明人： DRAPER, Kenneth, G. ,  KISNER, Daniel, L. ,  ANDERSON, Kevin, P. ,  CHAPMAN, Sharon

IPC分类号： C07H21/04 ,  C12Q1/68 ,  A61K48/00

CPC分类号： C12N15/1133 ,  A61K31/70 ,  A61K31/711 ,  A61K38/00 ,  C07H21/00 ,  C07K14/005 ,  C12N9/1252 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/334 ,  C12N2310/346 ,  C12N2310/3521 ,  C12N2310/3525 ,  C12N2710/16122 ,  C12Q1/705 ,  A61K2300/00 ,  C12N2310/3527

摘要： This invention concerns compositions and methods for the treatment of CMV infections. Antisense oligonucleotides are provided which are effective antiviral agents. In preferred embodiments, the oligonucleotides contain at least one 2'-methoxyethoxy modification and may be chimeric oligonucleotides.